When less treatment is the right amount of treatment
Until very recently, more treatment was assumed to mean better protection. That assumption is being tested, and in several parts of the breast cancer pathway, the latest evidence now points the other way.
Chemotherapy: what the newest evidence shows
- The phase 3 OPTIMA trial found that among patients with clinically high risk, ER positive, HER2 negative early breast cancer, those identified by a gene expression test as having a low risk of recurrence had similar five year outcomes whether or not they received chemotherapy alongside endocrine therapy [1].
- This adds high level evidence to a growing case for matching chemotherapy decisions to tumour biology rather than to clinical factors such as age or tumour size alone.
Surgery: rethinking a routine step
- Two trials, SOUND and INSEMA, found that omitting sentinel lymph node biopsy in women with clinically node negative, early stage breast cancer did not compromise disease free survival [2].
- Around 95% of participants in both trials had hormone receptor positive, HER2 negative disease, helping clinicians identify who may be a safe candidate for this less invasive approach.
Radiotherapy: matching intensity to risk
- A review of adjuvant radiotherapy strategies found that biological markers, including endocrine responsiveness and proliferation, are increasingly used to identify a low risk subgroup in whom omitting radiotherapy is a reasonable option [3].
- Hypofractionated regimens, or shorter courses delivering the same overall dose, are also becoming standard practice where a full course is still needed.
Why de-escalation can feel unsettling
- A study of patients and patient advocates found fear of recurrence was the most commonly reported barrier to accepting less treatment, cited by the large majority of those interviewed [4].
- The same study found no patient preferred the word de-escalation itself. Most favoured the phrase lowest effective dose, a reminder that language matters as much as evidence.
What patients tell us matters
- Research into patient preferences in early breast cancer treatment found that patients can weigh the benefits and risks of a risk stratified, biomarker driven approach differently to clinicians [5].
- Understanding these preferences is increasingly treated as part of designing treatment pathways, not an afterthought to them.
Deciding together
- A concept analysis of shared decision making in early stage breast cancer identified patient involvement, and the deliberate weighing of personal values, as central to how people experience good care [6].
- A study of newly diagnosed patients and their companions found that joint engagement in treatment decisions reduced anxiety and improved understanding of the choices being made [7]. In other words giving the patient a sense of agency has innumerable benefits.
Decisions made with, not for, the person
- Decision support tools, sometimes called decision aids, can support shared decision making by helping clarify the treatment options available and what matters most to each patient [8].
- Workflow barriers, including time pressure and the emotional weight of a new diagnosis, have limited how widely these tools are used in routine practice, pointing to an opportunity for better integration into everyday care.
The long-term vision
- We are working towards a future where increasingly personalised treatment pathways are supported by better information at every stage, from diagnosis through to long-term monitoring.
- Sentinel qCTC™ might be one small part of that future long-term vision.
Sentinel qCTC™ is an investigational technology platform undergoing development at Frontier Diagnostics Ltd. The platform has not reached design freeze and has not been submitted for regulatory review under IVDR (EU) 2017/746, UK MDR 2002, or FDA 21 CFR Part 809. It is not approved, cleared, or validated for diagnostic, clinical, or commercial research use. All scientific content relating to Sentinel qCTC™ describes developmental aims and does not constitute performance claims.
Sources
[1] OPTIMA: Genetic Test-Determined Chemo Is Noninferior to Chemo + Endocrine Therapy in Selected Patients With Early Breast Cancer, ASCO Daily News (2026)
[4] Patient perspectives on chemotherapy de-escalation in breast cancer, PMC
